Crinetics Pharmaceuticals (CRNX) Assets (2017 - 2026)

Crinetics Pharmaceuticals' Assets history runs 10 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, Assets rose 2.94% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (up 2.94% YoY), while the FY2025 annual figure was $1.1 billion, down 21.49% from the prior year.
• Assets for Q1 2026 stood at $1.4 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Assets was $1.4 billion in Q4 2024, with the low at $293.3 million in Q2 2023.
• The 5-year median for Assets is $935.5 million (2024), against an average of $825.7 million.
• The sharpest annual moves came in 2023 and 2024: Assets tumbled 30.46% in 2023, then soared 219.02% in 2024.
• Crinetics Pharmaceuticals' Assets stood at $352.2 million in 2022, then soared by 80.41% to $635.4 million in 2023, then soared by 125.79% to $1.4 billion in 2024, then declined by 21.49% to $1.1 billion in 2025, then advanced by 24.42% to $1.4 billion in 2026.
• Business Quant data shows CRNX's Assets at $1.4 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.2 billion in Q3 2025.